Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study. Adv Ther. 2009 Feb; 26(2):185-93.
View in:
PubMed
subject areas
Anti-HIV Agents
Atazanavir Sulfate
Budgets
CD4 Lymphocyte Count
Coronary Disease
Cost Savings
Cost-Benefit Analysis
Decision Support Techniques
Drug Costs
Drug Therapy, Combination
HIV Infections
Humans
Life Expectancy
Lopinavir
Markov Chains
Models, Econometric
Oligopeptides
Pyridines
Pyrimidinones
Quality-Adjusted Life Years
Ritonavir
Smoking
United States
authors with profiles
Kit N. Simpson